Treatment
Regional immunosuppression and associated systemic markers in focally relapsed sarcomatoid mesothelioma: case report
Journal for Immunotherapy of Cancer 2026 April 15 [Link] Hely Ollila, Prateek Kulkarni, Hyojin Kim, Pratiti Ankola, Navin K Chintala, Carlos Thomas, Jennifer L Sauter, Michael Offin, Prasad S Adusumilli Abstract A 52-year-old man presented with sarcomatoid diffuse pleural mesothelioma that had relapsed at an isolated site after a complete response to dual-immune checkpoint inhibition…
Read MoreMET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report
Translational Lung Cancer Research 2026 March 23 [Link] Yueying Chen, Mengyi Shen, Jiawen Lv, Yuwen Rui, Chunwei Xu, Dong Wang, Tangfeng Lv Abstract Background: Pleural mesothelioma (PM) is a rare malignancy globally, most frequently associated with alterations in tumor suppressor genes such as NF2, BAP1 and CDKN2A. In contrast, mutations or amplifications of the MET…
Read MoreFrom biology to therapy: current standards and emerging strategies in pleural mesothelioma
Frontiers in Oncology 2026 March 26 [Link] J H L T van Genugten, C J de Gooijer, Paul Baas Abstract Pleural mesothelioma (PM) is an aggressive malignancy with limited therapeutic options and poor long-term prognosis. Platinum-based chemotherapy has been the standard-of-care for most patients for decades. While the decoding of the genomic alterations in PM…
Read MorePseudo-senescence induced by palbociclib does not sensitise pleural mesothelioma cells to combinations with senolytics
Cell Death & Disease 2026 April 10 [Link] Iswarya Sreeram, Sílvia Plans-Marin, Mabel Cruz-Rodríguez, Elisabet Aliagas, Didac Palau-Gallinat, Cristina Muñoz-Pinedo, Ernest Nadal Abstract Pleural Mesothelioma (PM) is an aggressive neoplasm of the lung pleura with poor survival rates, highlighting the urgent need for novel therapeutic options. The CDK4/6 inhibitors abemaciclib and palbociclib have demonstrated promising…
Read MoreA case of delayed recurrence of pleural mesothelioma with intradural invasion
Surgical Neurology International 2026 March 20 [Link] Hidetoshi Sato, Rui Omichi, Yuto Nigami, Nobuyuki Shimokawa Abstract Background: Pleural mesothelioma (PM) is a tumor of the pleural epithelium with a poor prognosis. Asbestos exposure is closely related to its occurrence. To date, there have been 13 reports of PM with intradural invasion. Case description: A 73-year-old male was…
Read MoreThe Importance of 5-hmC Expression Loss in Diagnosis of Mesothelioma and the Relationship Between TROP2 Expression and Histomorphological Parameters in Mesotheliomas
International Journal of Surgical Pathology 2026 April 6 [Link] Hale Kivrak, İlke Evrim Secinti, Egemen Akincioglu, Elcin Kadan, Ertugrul Celik, Gulcin Guler Simsek Abstract Objectives: Mesothelioma is an aggressive cancer that is often not suitable for curative surgery. It can be difficult to distinguish from reactive processes and other malignancies, especially in small biopsies, and outcomes of systemic therapies remain…
Read MoreRadioimmunotherapy for Malignant Mesothelioma Targeting C-ERC/Mesothelin
Pharmaceuticals 2026 March 18 [Link] Hirofumi Hanaoka, Aiko Yamaguchi, Masahiro Maeda, Tatsuya Segawa, Noboru Oriuchi Abstract Background/Objectives: Malignant mesothelioma has a poor prognosis and limited therapeutic options. C-ERC/mesothelin is highly expressed in mesotheliomas and is a potential target for radioimmunotherapy (RIT). This study evaluated the radiolabeled anti-C-ERC/mesothelin antibody mAb 22A31 as a therapeutic agent. Methods:…
Read MoreCase Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case
Frontiers in Oncology 2026 March 9 [Link] Ilker Nihat Okten, Tuba Baydaş Abstract Background: Neurological immune-related adverse events (N-irAEs) represent rare but potentially fatal complications of immune checkpoint inhibitor (ICI) therapy. Among these, encephalitis associated with paraneoplatic neuronal antibodies poses a major diagnostic and therapeutic challenge, as it blurs the distinction between drug-induced toxicity and…
Read MoreDynamic evaluation of the glycolytic determinants LDH-A and GLUT-1 enhances prognostic significance and their inhibition affects the growth of mesothelioma spheroids
Molecular Metabolism 2026 May [Link] Marika A Franczak, Federica Borea, Valentina Donati, Marta Aliprandi, Amir Avan, Valentina Doldi, Giulia Bononi, Kin Yip Tam, Carlotta Granchi, Ryszard T Smolenski, Paolo A Zucali, Filippo Minutolo, Godefridus J Peters, Elisa Giovannetti Abstract Energy metabolism plays a crucial role in determining the aggressiveness of cancer. In this study, we…
Read MorePhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection
The Journal of Thoracic and Cardiovascular Surgery 2026 March 24 [Link] Andrea S Wolf, Shubham Gulati, Komal Dolasia, Bailey Fitzgerald, Jorge Gomez, David Yankelevitz, Andres Salazar, Alexander M Tsankov, Thomas Marron, Raja Flores Abstract Objective: To evaluate the role of neoadjuvant injection of the viral mimic poly-ICLC (polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose) in patients with pleural mesothelioma…
Read More
Skip to content